neurofibromatosis

European Union has approved AstraZeneca plc's (NASDAQ: AZN) Koselugo to treat children with neurofibromatosis type 1 and plexiform neurofibromas. Neurofibromatosis type 1 is characterized by soft lumps on and under the skin and skin pigmentation. The approval was granted by the...